

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Recombinant Anti-PKR antibody [EPR19374]

RRID:AB_2916271

Type: Antibody

Proper Citation

Abcam Cat# ab184257, RRID:AB_2916271

Antibody Information

URL: http://antibodyregistry.org/AB_2916271

Proper Citation: Abcam Cat# ab184257, RRID:AB_2916271

Target Antigen: PKR

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: Flow Cyt (Intra), ICC/IF, IP, WB

Antibody Name: Recombinant Anti-PKR antibody [EPR19374]

Description: This recombinant monoclonal targets PKR

Target Organism: rat, mouse, human

Clone ID: EPR19374

Antibody ID: AB_2916271

Vendor: Abcam

Catalog Number: ab184257

Record Creation Time: 20231110T031420+0000

Record Last Update: 20260901T060719+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-PKR antibody [EPR19374].

No alerts have been found for Recombinant Anti-PKR antibody [EPR19374].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shin H, et al. (2026) ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms. Cell reports, 45(3), 117026.

Yang G, et al. (2025) HSPA8 dampens SCAP/INSIG split and SREBP activation by reducing PKR-mediated INSIG phosphorylation. Cell reports, 44(3), 115339.

Ding Y, et al. (2024) Atherosclerosis-associated Inc_000048 activates PKR to enhance STAT1-mediated polarization of THP-1 macrophages to M1 phenotype. Neural regeneration research, 19(11), 2488.

Sinigaglia K, et al. (2024) An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation. Cell reports, 43(8), 114618.

Li T, et al. (2023) VMP1 affects endoplasmic reticulum stress sensitivity via differential modulation of the three unfolded protein response arms. Cell reports, 42(3), 112209.

Lukhele S, et al. (2022) The transcription factor IRF2 drives interferon-mediated CD8+ T??cell exhaustion to restrict anti-tumor immunity. Immunity, 55(12), 2369.